शुभ दीपावलीDiwali offer: 3 months free on yearly plans · ends 11 NovSee plans
ALBERTDAVDNSEAlbert David Limited· Pharmaceuticals & BiotechnologyHighNeutral
Announced Wed, 12 Nov, 2025 · 18:35 IST

Albert David Q2 FY26 Results: Revenue Down, Net Loss Reported

Revenue declinedNet loss reportedNegative operating cash flowResults View source PDFExplain this filing

ALBERTDAVD · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
-6.2%Reaction day
₹877.45
prior close
₹869.90
announcement price
After-mkt
timing
Nifty Microcap 250market · in no size index; the smallest one is used-0.1%-6.1% vs market
Pharmaceuticals peers, median of 157sector-0.0%-6.2% vs sector

On the reaction day the stock moved 6.1 pts less than Nifty Microcap 250 and 6.2 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
-2.6
10m
-3.8
15m
-4.9
30m
-4.8
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
-6.2-0.1-6.1-0.0-6.2
Next day
-7.6-0.2-7.4-0.4-7.1
2d
-7.1+0.4-7.5-0.3-6.8
3d
-9.6-0.4-9.2-1.0-8.5
4d
-8.4-0.6-7.8-1.3-7.1
5d
-8.7-0.9-7.8-1.5-7.2
1w
-11.3-3.0-8.3-3.2-8.2
15d
-10.5-3.9-6.7-3.4-7.1
1m
-14.5-4.8-9.6-4.0-10.4
2m
-16.6-7.8-8.8-6.6-10.0
3m
-14.2-7.2-7.0-8.5-5.7
UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 157Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Albert David Limited reported weak Q2 FY26 results. Revenue from operations fell to Rs. 87.24 crore from Rs. 98.44 crore in Q2 FY25 (down about 11 percent). The company swung to a net loss of Rs. 3.30 crore versus a profit of Rs. 18.07 crore last year. For the half year, revenue declined nearly 16 percent to Rs. 157.81 crore. Operating cash flow was negative at Rs. 20.85 crore. The statutory auditor issued an unmodified limited review report.

Likely market impact

Weak Q2 with revenue decline, net loss, and negative operating cash flow may weigh on the stock and investor sentiment in the near term.